Daniel Adelman, MD


Pulmonary, Critical Care, Allergy and Sleep Medicine

M.D., 1983 - School of Medicine, University of California Davis
  1. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
  2. Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet.
  3. Oral Immunotherapy for Peanut Allergy.
  4. AR101 Oral Immunotherapy for Peanut Allergy.
  5. Measuring Change In Small Intestinal Histology In Patients With Celiac Disease.
  6. Factors associated with villus atrophy in symptomatic coeliac disease patients on a gluten-free diet.
  7. A Novel Patient-Derived Conceptual Model of the Impact of Celiac Disease in Adults: Implications for Patient-Reported Outcome and Health-Related Quality-of-Life Instrument Development.
  8. A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac Disease.
  9. No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.
  10. Assessing Quality of Life in Patients with Common Variable Immunodeficiency: Why It Matters.
  11. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.
  12. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.
  13. Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.
  14. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
  15. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
  16. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.
  17. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
  18. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.
  19. Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium.
  20. Pharmacological approaches.
  21. Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells.
  22. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
  23. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
  24. Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin).
  25. Letter to the editor regarding the use of intravenous immunoglobulin (IVIG) in asthma.
  26. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects.
  27. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
  28. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo.
  29. Clinical differences among women with and without self-reported perimenstrual asthma.
  30. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.
  31. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.
  32. CD45 isoforms on human CD4+ T-cell subsets.
  33. Genetic basis of the primary immunodeficiency syndromes.
  34. Core content outline for clinical and laboratory immunology. AAAI Training Program Directors' Committee.
  35. The cross-reactivity and immunology of beta-lactam antibiotics.
  36. Isotype-specific regulation of human lymphocyte production of immunoglobulins by sustained exposure to vasoactive intestinal peptide.
  37. 13-cis retinoic acid enhances in vivo B-lymphocyte differentiation in patients with common variable immunodeficiency.
  38. Biologic response modifiers in primary immunodeficiency disorders.
  39. Penicillin allergy.
  40. Molecular characteristics of the cellular receptor for vasoactive intestinal peptide.
  41. Neuropeptides, mast cells and allergy: novel mechanisms and therapeutic possibilities.
  42. Elevated serum interleukin-6 associated with a failure in B cell differentiation in common variable immunodeficiency.
  43. Neuroimmunology.
  44. Acute respiratory emergencies in emergency treatment of the injured athlete.
  45. Abnormal T-cell subsets in normal persons.
  46. Fixed cutaneous eruptions to seminal-plasma challenge: a case report.
  47. Imipenem cross-reactivity with penicillin in humans.
  48. Retinoic acid induces the differentiation of B cell hybridomas from patients with common variable immunodeficiency.
  49. Recurrent bacterial infections and cellulitis in a 29-year-old woman with a history of hypogammaglobulinemia.
  50. Immediate hypersensitivity reactions to beta-lactam antibiotics.